Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse, Breast, vol.11, pp.442-450, 2002. ,
Incidence and prognosis in early onset breast cancer, Breast, vol.11, pp.30-35, 2002. ,
, Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer, Cochrane Database Syst Rev, vol.000487, 2002.
, Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, vol.352, pp.930-972, 1998.
, Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, vol.351, pp.1451-67, 1998.
, Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, pp.1687-717, 2005.
Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814), San Antonio Breast Cancer Symposium, p.37, 2004. ,
Treatment of lymph-node-negative, oestrogen-receptorpositive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, Lancet, vol.364, pp.858-68, 2004. ,
, Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial, J Natl Cancer Inst, vol.94, pp.1054-65, 2002.
HER2 and response to paclitaxel in node-positive breast cancer, N Engl J Med, vol.357, pp.1496-506, 2007. ,
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, vol.295, pp.1658-67, 2006. ,
, Cancer du sein infiltrant non métastatique -Questions d'actualité. Collection Avis & Recommandations, 2012.
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst, vol.88, pp.1456-66, 1996. ,
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group, Genet Med, vol.11, pp.3-14, 2009. ,
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements, Clin Chem, vol.54, pp.1-1, 2008. ,
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration, BMC Med, vol.10, p.51, 2012. ,
Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, vol.101, pp.1446-52, 2009. ,
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?, Expert Opin Ther Targets, vol.16, pp.17-22, 2012. ,
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J Natl Cancer Inst, vol.93, pp.913-933, 2001. ,
)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients, American Society of Clinical Oncology, vol.49, pp.1825-1860, 2013. ,
Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, J Natl Cancer Inst, vol.94, pp.116-144, 2002. ,
A nomogram predicting the probability of primary breast cancer survival at 2-and 5-years using pathological and biological tumor parameters, J Surg Oncol, vol.103, pp.746-50, 2011. ,
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma -a 7.5-year follow-up study, Tumori, vol.97, pp.532-541, 2011. ,
Prognostic significance of tumorrelated proteases as a function of the estrogen receptor status, Cancer Biol Ther, vol.11, pp.277-83, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01827405
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts, Clin Breast Cancer, vol.3, pp.196-200, 2002. ,
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer, Clin Breast Cancer, vol.5, pp.348-52, 2004. ,
High levels of uPA and PAI-1 predict a good response to anthracyclines, Breast Cancer Res Treat, vol.121, pp.615-639, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00612980
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue, Virchows Arch, vol.452, pp.277-83, 2008. ,
External quality assessment of trans-European multicentre antigen determinations (enzymelinked immunosorbent assay) of urokinasetype plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts, Br J Cancer, vol.78, pp.1434-1475, 1998. ,
Comparison of microarray-based RNA expression with ELISAbased protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome, J Cancer Res Clin Oncol, vol.136, pp.1709-1727, 2010. ,
UPA and PAI-1 analysis from fixed tissues -new perspectives for a known set of predictive markers, Curr Med Chem, vol.17, pp.4370-4377, 2010. ,
Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens, J Natl Cancer Inst, vol.101, pp.1028-1037, 2009. ,
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, pp.2817-2843, 2004. ,
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population, Cancer, vol.116, pp.3112-3120, 2010. ,
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study, J Clin Oncol, vol.28, pp.1829-1863, 2010. ,
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N Engl J Med, vol.320, pp.479-84, 1989. ,
, Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis, Ont Health Technol Assess Ser, vol.10, pp.1-57, 2010.
Utility of prognostic genomic tests in breast cancer practice, Ann Oncol, vol.24, pp.647-54, 2013. ,
Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, 2009. ,
Prognostic and predictive factors. Diagnosis and treatment of patients with primary and metastatic breast cancer, 2012. ,
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations, Ann Oncol, vol.23, pp.211-219, 2012. ,
Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review, J Natl Cancer Inst, vol.104, pp.1068-79, 2012. ,
NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology, J Natl Compr Canc Netw, vol.9, pp.1-32, 2011. ,
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 ,
, J Clin Oncol, vol.28, pp.1677-83, 2010.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, vol.11, pp.55-65, 2010. ,
Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer, J Cancer Res Clin Oncol, vol.136, pp.939-983, 2010. ,
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, vol.24, pp.3726-3760, 2006. ,
Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel, Cancer, vol.117, pp.1575-82, 2011. ,
, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer, Gen Med, vol.11, pp.66-73, 2009.
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients, Breast, vol.18, pp.171-175, 2009. ,
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study, J Clin Oncol, vol.29, pp.4279-85, 2011. ,
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories, J Clin Oncol, vol.28, pp.4300-4306, 2010. ,
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors, Appl Immunohistochem Mol Morphol, vol.18, pp.268-72, 2010. ,
Gene expression profiling for breast cancer prognosis in Chinese populations, Breast, vol.17, pp.172-181, 2011. ,
Histopathologic variables predict Oncotype DX recurrence score, Mod Pathol, vol.21, pp.1255-61, 2008. ,
Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score, Int J Surg Pathol, vol.17, pp.303-313, 2009. ,
Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?, Arch Pathol Lab Med, vol.134, pp.1697-701, 2010. ,
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers, Cancer, vol.116, pp.5161-5168, 2010. ,
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score, Br J Cancer, vol.105, pp.1342-1347, 2011. ,
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer, Cancer Invest, vol.28, pp.978-82, 2010. ,
Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptorpositive breast cancer, Appl Immunohistochem Mol Morphol, vol.19, pp.431-437, 2011. ,
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, vol.29, pp.4273-4281, 2011. ,
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer, Clin Chem, vol.53, pp.1084-91, 2007. ,
Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer, PLoS ONE, vol.4, p.5911, 2009. ,
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization, BMC Cancer, vol.11143, 2011. ,
Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, pp.530-536, 2002. ,
A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, vol.347, pp.1999-2009, 2002. ,
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, vol.98, pp.1183-92, 2006. ,
Validation of 70-gene prognosis signature in node-negative breast cancer, Breast Cancer Res Treat, vol.117, pp.483-95, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00478268
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature, Br J Cancer, vol.103, pp.1788-93, 2010. ,
Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice, Ann Oncol, vol.22, pp.2021-2051, 2011. ,
Use of a genomic test (Mamma-Print TM ) in daily clinical practice to assist in risk stratification of young breast cancer patients, Arch Gynecol Obstet, vol.283, pp.597-602, 2011. ,
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study, Breast Cancer Res Treat, vol.116, pp.295-302, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00478252
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature, Ann Surg Oncol, vol.17, pp.1406-1419, 2010. ,
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age, Ann Oncol, vol.21, pp.717-739, 2010. ,
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer, Breast Cancer Res Treat, vol.120, pp.655-61, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00535448
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, Breast Cancer Res Treat, vol.119, pp.551-559, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00535339
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial, Eur J Cancer, vol.45, pp.1201-1209, 2009. ,
Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil, Rev Assoc Med Bras, vol.56, pp.186-91, 2010. ,
Cost-effectiveness of 70-gene MammaPrint signature in nodenegative breast cancer, Am J Manag Care, vol.16, pp.333-375, 2010. ,
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph nodepositive breast cancer, J Natl Cancer Inst, vol.104, pp.56-66, 2012. ,
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am J Manag Care, vol.11, pp.313-337, 2005. ,
US insurance program's experience with a multigene assay for early-stage breast cancer, Am J Manag Care, vol.17, pp.194-202, 2011. ,
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization, Value Health, vol.13, pp.381-388, 2010. ,
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogenreceptor-positive, early-stage breast cancer in Japan, Breast Cancer Res Treat, vol.112, pp.175-87, 2008. ,
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph nodenegative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03), Breast Cancer Res Treat, vol.127, pp.739-788, 2011. ,
Economic evaluation of the 70-gene prognosis-signature (MammaPrint ® ) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan, Breast Cancer Res Treat, vol.133, pp.759-68, 2012. ,
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer, Breast Cancer Res Treat, vol.133, pp.1115-1138, 2012. ,
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies, Cancer, vol.109, pp.1011-1019, 2007. ,
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications, Gen Med, vol.7, pp.380-389, 2005. ,
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer, Eur J Cancer, vol.46, pp.1382-91, 2010. ,
Head-tohead comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance, Breast Cancer Res Treat, vol.131, pp.627-663, 2012. ,
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer, Oncologist, vol.15, pp.457-65, 2010. ,
Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer, Am J Manag Care, vol.17, pp.455-64, 2011. ,
Cost-effectiveness of a chemotherapy predictive test] Analyse coûtefficacité d'un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX ® ) en France, Bull Cancer, vol.99, pp.907-921, 2012. ,
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model, Cancer, vol.118, pp.5163-70, 2012. ,
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management. ScHARR University of Sheffield, 2011. ,